Sevoflurane aggravate minimal hepatic encephalopath in cirrhosis patients
Sevoflurane aggravate minimal hepatic encephalopathy in cirrhosis patients compared to propofol
National Natural Science Foundation of China
60 participants
Jan 1, 2012
Interventional
Conditions
Summary
Patients with minimal hepatic encephalopathy (MHE) have impaired motor function and visuomotor cordination, which make them unsafe in their life. Evaluation of MHE stage in surgery patients with hepatic cirrhosis is an important problem for the inhalation of anesthetics. We have previously observed that sevoflurane induced increased MHE scores in non-hepatic surgery patients with cirrhosis, suggesting that inhaled anesthetics can. In this study, we try to demonstrate the effect of sevoflurane on MHE in cirrhosis patients by a randomized controlled clinical observation. This study would be helpful for the perioperative anesthetic application in patients with cirrhosis.
Eligibility
Inclusion Criteria1
- patients who had evidence of cirrhosis by clinical, biochemical, and/or histological criteria with ASA class 1 or 2 scheduled for elective surgery
Exclusion Criteria1
- patients with active bleeding or with overt encephalopathy, patients with known allergy to sedative, known significant respiratory disease, active neurological impairment, advanced or decompensated liver disease (CP score >9, Child-Pugh class C), ongoing alcohol or drug abuse, psychiatric illness, monocular vision, mental impairment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2-3% sevoflurane (to maintain bispectral index values 40-60) inhaled during the operation (2-4h, vary on a case by case basis depending on the operation).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000910808